Summary
Perindopril Arginine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypertension would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypertension. ClinicalTrials.gov lists 2 registered trials linking Perindopril Arginine to Hypertension: 2 have completed. The most advanced is Phase 3 (NCT01556997). It plans or enrolled 837 participants. Registration activity spans 2012 to 2018. The literature layer holds 7 publications for this pair: 1 systematic review, 1 randomised controlled trial publication and 5 clinical trial publications. Publication years run from 2015 to 2021. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Essential Hypertension ranks 376 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Not well-characterized as population baseline; routinely framed as irreversible in clinical culture despite contrary trial evidence.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 45.0 (trials 9.0, literature 16.0, tier 15, approved bonus 5.0) |
| Registered trials | 2 total: 0 recruiting, 0 active / not yet recruiting, 2 completed, 0 other |
| Linked publications | 7 (5 clinical trial publications, 1 systematic review, 1 randomised controlled trial publication) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05288400 | Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension. 2018 | completed | Phase 3 | 150 |
| NCT01556997 | Perindopril Amlodipine for the Treatment of Hypertension 2012 | completed | Phase 3 | 837 |
Published literature
- Clinical trial publication A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patients With Essential HypertensionLee HY, Kim KI, Ihm SH et al. · Clinical therapeutics · 2021 · PMID 34503866
- Clinical trial publication Effect of Perindopril/Indapamide on Cerebral Blood Flow in Middle-Aged, Treatment-Naïve Patients with HypertensionOstroumova TM, Ostroumova OD, Parfenov VA et al. · Advances in therapy · 2020 · PMID 33026579
- Systematic review Perindopril arginine and amlodipine besylate for hypertension: a safety evaluationElliott WJ, Bistrika EA · Expert opinion on drug safety · 2018 · PMID 29065722
- Clinical trial publication An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK)Bicknell CD, Kiru G, Falaschetti E et al. · European heart journal · 2016 · PMID 27371719
- Clinical trial publication Efficacy and Safety of Fixed-Dose Perindopril Arginine/Amlodipine in Hypertensive Patients Not Adequately Controlled with Amlodipine 5 mg or Perindopril tert-Butylamine 4 mg MonotherapyHu D, Sun Y, Liao Y et al. · Cardiology · 2016 · PMID 26771522
- Clinical trial publication [Efficacy comparison between 5 mg perindopril arginine salt and 4 mg perindopril tert-butylamine salt for patients with mild to moderate essential hypertension]Qi L, Zhao S, Li H et al. · Zhonghua xin xue guan bing za zhi · 2015 · PMID 26652987
- Randomized controlled trial Efficacy and safety of perindopril arginine + amlodipine in hypertensionElliott WJ, Whitmore J, Feldstein JD et al. · Journal of the American Society of Hypertension : JASH · 2015 · PMID 25804495
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Perindopril Arginine approved for Hypertension?
Perindopril Arginine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypertension would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypertension. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Perindopril Arginine in clinical trials for Hypertension?
ClinicalTrials.gov lists 2 registered trials linking Perindopril Arginine to Hypertension: 2 have completed. The most advanced is Phase 3 (NCT01556997). It plans or enrolled 837 participants. Registration activity spans 2012 to 2018.
What does the evidence show for Perindopril Arginine in Hypertension?
Perindopril Arginine has both completed registered trials and synthesis-level publications linked to Hypertension. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.